BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ipsen DH, Tveden-Nyborg P. Extracellular Vesicles as Drivers of Non-Alcoholic Fatty Liver Disease: Small Particles with Big Impact. Biomedicines 2021;9:93. [PMID: 33477873 DOI: 10.3390/biomedicines9010093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets? Biomedicines 2021;9:365. [PMID: 33807461 DOI: 10.3390/biomedicines9040365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhu Q, Li H, Ao Z, Xu H, Luo J, Kaurich C, Yang R, Zhu PW, Chen SD, Wang XD, Tang LJ, Li G, Huang OY, Zheng MH, Li HP, Liu F. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis. J Nanobiotechnology 2022;20:349. [PMID: 35897102 DOI: 10.1186/s12951-022-01540-4] [Reference Citation Analysis]
3 Sun J, Zhang D, Li Y. Extracellular Vesicles in Pathogenesis and Treatment of Metabolic Associated Fatty Liver Disease. Front Physiol 2022;13:909518. [DOI: 10.3389/fphys.2022.909518] [Reference Citation Analysis]
4 Baumgartner S, Shiri-Sverdlov R. NASH and Systemic Complications: From Basic to Clinical Research. Biomedicines 2021;9:1913. [PMID: 34944726 DOI: 10.3390/biomedicines9121913] [Reference Citation Analysis]